Skip to content 
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. more
| Time Frame | KLRS | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.72% | -1.08% | -1.38% |
| 1-Month Return | -6.39% | -0.47% | -1.81% |
| 3-Month Return | 62.29% | 2.13% | 1.38% |
| 6-Month Return | 279.39% | 17.04% | 5.68% |
| 1-Year Return | -12.45% | 6.56% | 11.74% |
| 3-Year Return | -93.97% | 16.78% | 65.15% |
| 5-Year Return | -99.09% | 34.34% | 73.68% |
| 10-Year Return | -98.52% | 137.88% | 260.03% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | 73.00K | 1.12M | - | - | - | [{"date":"2020-12-31","value":6.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Profit | (73.00K) | (1.12M) | - | - | - | [{"date":"2020-12-31","value":-7300000,"profit":false},{"date":"2021-12-31","value":-111700000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 71.24M | 168.70M | 14.01M | 13.46M | 55.26M | [{"date":"2020-12-31","value":42.23,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":8.3,"profit":true},{"date":"2023-12-31","value":7.98,"profit":true},{"date":"2024-12-31","value":32.75,"profit":true}] |
| Operating Income | (71.31M) | (169.82M) | (14.01M) | (13.46M) | (55.26M) | [{"date":"2020-12-31","value":-7130900000,"profit":false},{"date":"2021-12-31","value":-16981800000,"profit":false},{"date":"2022-12-31","value":-1400600000,"profit":false},{"date":"2023-12-31","value":-1346400000,"profit":false},{"date":"2024-12-31","value":-5525600000,"profit":false}] |
| Total Non-Operating Income/Expense | - | - | (1.71M) | (1.92M) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-171400000,"profit":false},{"date":"2023-12-31","value":-192200000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Pre-Tax Income | (69.78M) | (170.96M) | (15.48M) | (14.70M) | (58.77M) | [{"date":"2020-12-31","value":-6978400000,"profit":false},{"date":"2021-12-31","value":-17095500000,"profit":false},{"date":"2022-12-31","value":-1548500000,"profit":false},{"date":"2023-12-31","value":-1469900000,"profit":false},{"date":"2024-12-31","value":-5876900000,"profit":false}] |
| Income Taxes | - | 1.01M | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | - | - | (15.48M) | (14.70M) | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-1548500000,"profit":false},{"date":"2023-12-31","value":-1469900000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (69.78M) | (171.96M) | (15.48M) | (14.70M) | (58.77M) | [{"date":"2020-12-31","value":-6978400000,"profit":false},{"date":"2021-12-31","value":-17196200000,"profit":false},{"date":"2022-12-31","value":-1548500000,"profit":false},{"date":"2023-12-31","value":-1469900000,"profit":false},{"date":"2024-12-31","value":-5876900000,"profit":false}] |
| EPS (Diluted) | (5.54) | (2.74) | (2.20) | (1.83) | (4.41) | [{"date":"2020-12-31","value":-554,"profit":false},{"date":"2021-12-31","value":-274,"profit":false},{"date":"2022-12-31","value":-220,"profit":false},{"date":"2023-12-31","value":-183,"profit":false},{"date":"2024-12-31","value":-441.23,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| KLRS | |
|---|---|
| Cash Ratio | 12.70 |
| Current Ratio | 12.89 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| KLRS | |
|---|---|
| ROA (LTM) | -63.50% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| KLRS | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.48 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| KLRS | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 4.01 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Kalaris Therapeutics, Inc. (KLRS) share price today is $8.65
Yes, Indians can buy shares of Kalaris Therapeutics, Inc. (KLRS) on Vested. To buy
Yes, you can purchase fractional shares of Kalaris Therapeutics, Inc. (KLRS) via the Vested app. You can start investing in Kalaris Therapeutics, Inc. (KLRS) with a minimum investment of $1.
You can invest in shares of Kalaris Therapeutics, Inc. (KLRS) via Vested in three simple steps:
The 52-week high price of Kalaris Therapeutics, Inc. (KLRS) is $12.9. The 52-week low price of Kalaris Therapeutics, Inc. (KLRS) is $2.14.
The price-to-earnings (P/E) ratio of Kalaris Therapeutics, Inc. (KLRS) is
The price-to-book (P/B) ratio of Kalaris Therapeutics, Inc. (KLRS) is 4.01
The dividend yield of Kalaris Therapeutics, Inc. (KLRS) is 0.00%
The market capitalization of Kalaris Therapeutics, Inc. (KLRS) is $167.95M
The stock symbol (or ticker) of Kalaris Therapeutics, Inc. is KLRS
Consider the share price of Kalaris Therapeutics, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kalaris Therapeutics, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Kalaris Therapeutics, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kalaris Therapeutics, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Kalaris Therapeutics, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kalaris Therapeutics, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
